Net Loss Per Share (Tables)

12 Months Ended

Mar. 31, 2026

Net Loss Per Share [Abstract]

Schedule of Basic and Diluted Loss Per Share

The components of basic and diluted loss per share were as follows:

		Year ended March 31,
(In USD, except loss per share)		2026				2025

Net loss available for common shareholders (A)		$	(14,621,113	)		$	(25,622,303	)
Weighted average outstanding shares of common stock (B) #^			11,451,192				490,140
Dilutive effect of potentially dilutive outstanding securities			-				-
Common Stock and Common Stock Equivalents			11,451,192				490,140
Loss per share
Basic (A/B)		$	(1.28	)		$	(52.28	)
Diluted (A/C)		$	(1.28	)		$	(52.28	)

#

Prior period numbers have been adjusted to reflect the First Reverse Stock Split and the Second Reverse Stock Split of the Common Stock at a ratio of 1-for-100 and 1-for-20 respectively. (Refer Note 3A)

^

Including pre-funded/cashless exercise warrants.

Schedule of Diluted Loss Per Share Anti-Dilutive

The following potentially dilutive outstanding securities as of March 31, 2026 and March 31, 2025 were excluded from the computation of diluted loss per share because their effect would have been anti-dilutive for the years presented, or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the year.

		Year ended March 31,
		2026				2025
Convertible preferred stock
Preferred stock warrants
Stock options*			16				16
Restricted Stock Units (Refer Note 26)			4,216,250				17,966
Public warrants			11,500,000				11,500,000
Private warrants			19,180				19,180
Warrants issued along with redeemable promissory note			5,297				5,297
Warrants issued in February 2026 private placement offering			939				-
Warrants issued in November 2024 and December 2024 offering (including Second and Third closing of December offering)			3,472,777				12,335,519
Total			19,214,459				23,877,978

*

In 2012, the Company adopted its 2012 Equity Incentive Plan, under which the Company may grant options and restricted stock to eligible participants. The plan is equity settled. Options are generally granted for a term of ten years. Options have a graded vesting period of up to four years and the expenses are recorded on a straight-line basis over the requisite service period for each separately vesting portion of the awards. The Company cancelled certain outstanding options at the time of Reverse Recapitalization. The remaining 16 fully vested options were assumed by the Company on the Reverse Recapitalization date, exercisable at exercise price ranging from $120 to $300.